and/or patients with a high metabolic burden who have already entered the fertility pathway but encountered metabolic-related barriers during ART (e.g., high OHSS risk, suboptimal oocyte/embryo quality, or cycle cancelation)
Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use these medications, as studies in rodents have shown an increased risk of thyroid C-cell tumours (though the relevance to humans remains uncertain)
Ingredients: Aqua, glycerin, dicaprylyl ether, alcohol denat, glyceryl stearate se, isopropyl palmitate, cetearyl alcohol, argania spinosa kernel oil, dimethicone, carbomer, sodium cetearyl sulfate, sodium hydroxide, trisodium edta, phenoxyethanol, parfum
PHD activates the pseudohypoxic response by stabilizing HIF-1, which is a well-known tumorigenesis enhancer, and as a transcription factor, maintains the metabolic reprogramming of cancer cells to support their survival 127
Cammalleri, M
